Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Regeneron (REGN) PT Lifted to $523 at Leerink Partners
April 4, 2016 6:21 AM EDTLeerink Partners analyst Geoffrey Porges reiterated an Outperform rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $523.00 (from $505.00) after dupilumab was substantially de-risked for the atopic dermatitis (AD) indication, and, they believe, for other indications as well (for safety).
"Our... More
Regeneron (REGN) Shares Cross Above $400 Level
April 1, 2016 12:12 PM EDTRegeneron (NASDAQ: REGN) shares keep ramping higher. The stock is now up 11.3 percent and has crossed above the $400 levle.
Earlier, Regeneron and Sanofi announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD) met their primary endpoints.
... MoreBaird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
April 1, 2016 11:52 AM EDTBaird reiterated an Outperform rating and $526.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's release of Dupilumab's phase III atopic dermatitis phase III data. The two Phase III studies, SOLO 1 and SOLO 2, enrolled 1,379 adult patients with moderate-to-severe AD. The FDA's... More
Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520
April 1, 2016 10:55 AM EDTRoth Capital analyst Joseph Pantginis trimmed his price target on Regeneron Pharma (NASDAQ: REGN) to $520.00 (from $555.00) but maintained a Buy rating after Dupilumab (Breakthrough Designation) delivered two positive Phase III studies in moderate-to-severe atopic dermatitis.
"The BLA filing is expected in 3Q16 and... More
